VX-745 |cas 209410-46-8 |DC Chemicals|Supplier|Price|Buy_DC_Chem...

来自 : 新浪博客 发布时间：2021-03-24

Chemicals|Supplier|Price|Buy
DC ChemicalsSupply:VX-745 ,cas 209410-46-8, Cat No.DC4173, In stockContact: website:www.dcchemicals.com,sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,Tel: +86-21-61454686;Fax:+86-21-61642730；Product name: VX-745, Synonym: VX 745,VX745, Cat No. DC4173, Cas: 209410-46-8,ChemicalName:5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one,Molecular Formula: C19H9Cl2F2N3OS, MW: 436.26VX-745 Cas#209410-46-8.Purity:99%.Best Price and Quality inthe Market!Supplied by DC Chemicals! VX-745 is a potent andselective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nMand 220 nM, respectively.VX-745 is an antiarthritic Drugs. Its activities andapplication include: Myelodysplastic Syndrome Therapy, OncolyticDrugs, Rheumatoid Arthritis, Treatment of, treatment ofmusculoskeletal connective tissue diseases, AntiinflammatoryDrugs, p38 Protein Kinase.VX-745 is a lead anti-inflammatory candidate, small-moleculeinhibitor of mitogen-activated protein kinase (MAPK), is underdevelopment by Vertex Pharmaceuticals Inc in association withKissei Pharmaceutical Co Ltd for the potential treatment ofrheumatoid arthritis (RA) . VX-745 was introduced by Vertex as apotential antiinflammatory drug for the treatment of RA in a pilotphase II trial initiated in November 1999. In June 2000, phase IItrials were still ongoing and in January 2001, Vertex initiated arandomized, double-blind, placebo-controlled phase II trial inadult patients with RA, with the objective of evaluating clinicalresponse rates, self-reported patient health assessments andpharmacodynamic markers of drug activity. During the 33rd AnnualMeeting of the American Chemical Society in May 2000, VX-745 wasreported to be active against several isotypes of p38 MAPK,including p38alpha, p38beta and p38gamma . The targeting of p38MAPK by VX-745 was associated with the suppression of the releaseof inflammatory mediators, including interleukin (IL)-1beta andtumor necrosis factor (TNF)alpha, known to be implicated inexacerbating the pathophysiology of RA. [source: Curr Opin InvestigDrugs. 2001 Aug;2(8):1070-6.]For the detailed information about thesolubility of VX-745 in water, the solubility ofVX-745 in DMSO, the solubility of VX-745in PBS buffer, the animal experiment of VX-745,the in vivo and in vitro test of VX-745 ,the cell experiment ofVX-745 ,the IC50 and EC50 of VX-745 please contact DCChemicals.